APA
Click to copy
Vilgelm, A., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., … Richmond, A. (2015). Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Research.
Chicago/Turabian
Click to copy
Vilgelm, A., Jeff S. Pawlikowski, Yan Liu, Oriana E. Hawkins, Tyler A. Davis, Jessica Smith, K. Weller, et al. “Mdm2 And Aurora Kinase a Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells.” Cancer research (2015).
MLA
Click to copy
Vilgelm, A., et al. “Mdm2 And Aurora Kinase a Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells.” Cancer Research, 2015.
BibTeX Click to copy
@article{a2015a,
title = {Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.},
year = {2015},
journal = {Cancer research},
author = {Vilgelm, A. and Pawlikowski, Jeff S. and Liu, Yan and Hawkins, Oriana E. and Davis, Tyler A. and Smith, Jessica and Weller, K. and Horton, L. and McClain, Colt M. and Ayers, G. and Turner, D. and Essaka, David C. and Stewart, C. and Sosman, J. and Kelley, M. and Ecsedy, J. and Johnston, J. and Richmond, A.}
}
Therapeutics that induce cancer cell senescence can block cell proliferation and promote immune rejection. However, the risk of tumor relapse due to senescence escape may remain high due to the long lifespan of senescent cells that are not cleared. Here, we show how combining a senescence-inducing inhibitor of the mitotic kinase Aurora A (AURKA) with an MDM2 antagonist activates p53 in senescent tumors harboring wild-type 53. In the model studied, this effect is accompanied by proliferation arrest, mitochondrial depolarization, apoptosis, and immune clearance of cancer cells by antitumor leukocytes in a manner reliant upon Ccl5, Ccl1, and Cxcl9. The AURKA/MDM2 combination therapy shows adequate bioavailability and low toxicity to the host. Moreover, the prominent response of patient-derived melanoma tumors to coadministered MDM2 and AURKA inhibitors offers a sound rationale for clinical evaluation. Taken together, our work provides a preclinical proof of concept for a combination treatment that leverages both senescence and immune surveillance to therapeutic ends.